AstraZeneca, Alexion's mysathenia gravis treatment enters crowded market
AstraZeneca and Alexion won FDA approval Monday for their self-administered generalized myasthenia gravis (gMG) drug Klygefa. The drug, also known as gefurulimab, is a once-weekly treatment for patients who have anti-acetylcholine receptor antibodies, a harmful ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.